Article
Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer.
Cancer chemotherapy and pharmacology - 1 Jan 2015
Hochster H S, Uboha N, Messersmith W, Gold P J, ONeil B H, Cohen D, Denlinger C, Cohen S, Leichman C G, Leichman L, Lenz H-J
Abstract excerpt
BACKGROUND: More than half of colorectal tumors harbor activating mutations in RAS/RAF proteins. Selumetinib (AZD6244, ARRY-142886) is a small molecule kinase inhibitor targeting MEK kinase, downstream of RAS. We examined the efficacy and safety of selumetinib with irinotecan in second-line therapy. METHODS: Patients with K-RAS mutated colorectal cancer, progressing on first-line oxaliplatin-based chemotherapy...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.